Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schöffski Patrick, Sanfilippo Roberta, Martín-Broto Javier, Kawai Akira, Desai Jayesh, LoRusso Patricia, Maki Robert G, Jones Robin L, Blay Jean-Yves, Smrke Alannah, Abdul Razak Albiruni, Italiano Antoine, Sebio Ana, Bahleda Rastislav, Lee Yeh Chen, van der Graaf Winette T A, Zhang Xing, Biyukov Tsvetan, Teufel Michael, Fu Eric, Lahmar Mehdi, Wagner Andrew J
Аннотация
PURPOSE: The phase 2/3 Brightline-1 trial (NCT05218499) assessed the MDM2-p53 antagonist brigimadlin versus standard-of-care doxorubicin as first-line treatment for MDM2-amplified, locally advanced/metastatic dedifferentiated liposarcoma (DDLPS).
PATIENTS AND METHODS: Patients with MDM2-amplified, locally advanced or metastatic, unresectable, progressive, or recurrent DDLPS were eligible. In phase 2, patients received oral brigimadlin 30 or 45 mg, or intravenous doxorubicin 75 mg/m2 (all once every 3 weeks). Following a preplanned analysis, in phase 3 patients received brigimadlin 45 mg or doxorubicin 75 mg/m2. The primary endpoint was PFS by blinded central independent review.
RESULTS: Between April 13, 2022, and Aug 22, 2023, 148 patients received brigimadlin 45 mg and 162 received doxorubicin. At data cutoff, median PFS was 8.4 months with brigimadlin versus 7.2 months with doxorubicin [Hazard Ratio 0.79 (95% Confidence Interval, 0.6-1.06), P = 0.096]; the primary endpoint was not met. The confirmed objective response rate was 22.3% with brigimadlin and 8.6% with doxorubicin. The most-common grade ≥3 adverse events with brigimadlin were neutropenia (n = 54, 36.7%) and thrombocytopenia (n = 41, 27.9%). Translational analysis demonstrated that brigimadlin activated the TP53 pathway but no biomarkers predictive of efficacy were identified.
CONCLUSIONS: While brigimadlin showed activity in this patient population, the median PFS with doxorubicin was substantially longer than anticipated and the primary endpoint of PFS was not met. The safety profile of brigimadlin also did not appear to be more manageable than that of doxorubicin. The translational results will guide future clinical investigations of MDM2-p53 antagonists.
PATIENTS AND METHODS: Patients with MDM2-amplified, locally advanced or metastatic, unresectable, progressive, or recurrent DDLPS were eligible. In phase 2, patients received oral brigimadlin 30 or 45 mg, or intravenous doxorubicin 75 mg/m2 (all once every 3 weeks). Following a preplanned analysis, in phase 3 patients received brigimadlin 45 mg or doxorubicin 75 mg/m2. The primary endpoint was PFS by blinded central independent review.
RESULTS: Between April 13, 2022, and Aug 22, 2023, 148 patients received brigimadlin 45 mg and 162 received doxorubicin. At data cutoff, median PFS was 8.4 months with brigimadlin versus 7.2 months with doxorubicin [Hazard Ratio 0.79 (95% Confidence Interval, 0.6-1.06), P = 0.096]; the primary endpoint was not met. The confirmed objective response rate was 22.3% with brigimadlin and 8.6% with doxorubicin. The most-common grade ≥3 adverse events with brigimadlin were neutropenia (n = 54, 36.7%) and thrombocytopenia (n = 41, 27.9%). Translational analysis demonstrated that brigimadlin activated the TP53 pathway but no biomarkers predictive of efficacy were identified.
CONCLUSIONS: While brigimadlin showed activity in this patient population, the median PFS with doxorubicin was substantially longer than anticipated and the primary endpoint of PFS was not met. The safety profile of brigimadlin also did not appear to be more manageable than that of doxorubicin. The translational results will guide future clinical investigations of MDM2-p53 antagonists.